Archive: 2026/02

DOACs like apixaban and rivaroxaban offer fewer bleeding risks and no dietary restrictions compared to warfarin, making them the preferred choice for most patients. But warfarin still matters for specific conditions and cost-sensitive cases.

States are using MAC lists, anti-gouging laws, and PBM reforms to control rising generic drug costs in Medicaid. Despite generics making up 85% of prescriptions, spending is still high due to price spikes and supply issues. Learn how states are balancing savings with access.